We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Read MoreHide Full Article
Key Takeaways
Medicare's GLP-1 Bridge program expands access to weight-loss drugs for eligible U.S. seniors.
NVO and LLY could benefit as millions of Medicare beneficiaries become eligible for GLP-1 therapies.
ETFs like OZEM offer diversified exposure to companies tied to the expanding weight-loss market.
In a landmark move beginning July 1, 2026, Medicare, under its "GLP-1 Bridge" demonstration program, is set to provide eligible U.S. seniors with access to popular weight-loss medications like Wegovy, Zepbound, and Foundayo for a copay of just $50 per month. This historic decision, which sidesteps a decades-old federal law banning Medicare coverage for weight-loss drugs, is set to unlock millions of new patients for major obesity drugmakers like Novo Nordisk (NVO - Free Report) and Eli Lilly (LLY - Free Report) .
For investors, this development signals a significant catalyst for the booming weight-loss drug market. While the rally in GLP-1 giants has already been substantial, the latest Medicare coverage expansion has added a new, powerful growth driver.
For those looking to capitalize on this trend without betting on a single company, specialized Exchange-Traded Funds (ETFs) focused on GLP-1 drugs offer a compelling way to gain diversified exposure to the industry-wide rally.
To understand why these ETFs are poised to benefit, one must first grasp the scale of the obesity drug market's expansion and its growth opportunities in the United States, in addition to the specific impact of this new coverage.
The Booming U.S. Obesity Drug Market
The U.S. weight-loss drug market has experienced explosive growth, driven by a combination of medical innovation and soaring patient demand. According to CDC data, every single U.S. state and territory maintains an obesity prevalence of 25% or higher, with the condition affecting 40% of all U.S. adults. This widespread public health crisis results in nearly $173 billion in annual healthcare expenditures, putting weight-loss drugs, commonly known as GLP-1s, at center stage.
This growth is further fueled by aggressive pipeline expansion from the industry's two dominant players. Eli Lilly recently strengthened its position with the launch of its oral GLP-1, Foundayo, in early April 2026, joining its blockbuster injection Zepbound. Novo Nordisk rolled out an oral version of its flagship Wegovy in January 2026, giving patients a convenient, non-injectable alternative.
Medicare Coverage Unlocks New Growth Opportunities
Obesity among older Americans has risen sharply, nearly doubling over the last few decades to affect roughly 40% of seniors aged 65 and older. The Medicare GLP-1 Bridge program addresses this previously untapped pool by making therapeutics affordable for a massive segment of the 69 million Medicare beneficiaries.
The financial implications are staggering. A Kaiser Family Foundation (KFF) analysis estimates that 3.8 million beneficiaries immediately meet the clinical criteria for the program. KFF projects that if even 10% to 25% of these eligible seniors participate, the program will inject between $1.3 billion and $3.3 billion directly into the market. If adoption reaches 50%, that revenue pipeline balloons up to $10 billion.
Novo Nordisk and Eli Lilly estimate that 15 to 20 million older adults in Medicare could ultimately qualify for their weight loss medications (as cited in CNBC). So, the latest Medicare Coverage of GLP-1 drugs should translate into direct revenue growth for these two drug giants.
This highly visible profit margin may also force other pharma giants to accelerate their pipelines. Pfizer (PFE - Free Report) recently finalized a massive $10 billion acquisition of obesity biotech Metsera to secure long-acting GLP-1 assets, while Amgen (AMGN - Free Report) is aggressively advancing its own experimental weight-loss therapy candidate like maridebart cafraglutide.
Weight Loss ETFs to Rally
To seamlessly capture this expanding ecosystem of the weight loss market, the following specialized ETFs featuring the obesity drug giants are poised to rally in the coming days:
This fund, with net assets worth $54 million, offers exposure to 25 companies that are involved in the manufacturing of weight loss drugs, including GLP-1 agonists. Its top three holdings include: NVO (with 12.96% weightage), LLY (12.69%) and PFE (6.38%). AMGN holds the 10th spot in this fund, with 3.85% weightage.
OZEM has surged 27.1% over the past year. The fund charges 59 basis points (bps) as fees.
Amplify Weight Loss Drug & Treatment ETF (THNR - Free Report)
This fund, with net assets worth $4.4 million, offers exposure to 20 companies that are expected to economically benefit from weight loss drug development. Its top three holdings include: NVO (9.76%), LLY (9.26%) and Scholar Rock (5.71%). AMGN holds the seventh spot in this fund, with 4.58% weightage.
THNR has risen 11.8% over the past year. The fund charges 59 bps as fees.
This fund, with net assets worth $54.6 million, offers exposure to 45 companies advancing prevention and treatment across chronic conditions, including heart disease, diabetes, and obesity. Its top three holdings include: LLY (11.86%), UnitedHealth (5.53%) and NVO (5.22%).
HRTS has rallied 26.5% over the past year. The fund charges 75 bps as fees.
View the Zacks #1 Rank List
Image: Bigstock
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Key Takeaways
In a landmark move beginning July 1, 2026, Medicare, under its "GLP-1 Bridge" demonstration program, is set to provide eligible U.S. seniors with access to popular weight-loss medications like Wegovy, Zepbound, and Foundayo for a copay of just $50 per month. This historic decision, which sidesteps a decades-old federal law banning Medicare coverage for weight-loss drugs, is set to unlock millions of new patients for major obesity drugmakers like Novo Nordisk (NVO - Free Report) and Eli Lilly (LLY - Free Report) .
For investors, this development signals a significant catalyst for the booming weight-loss drug market. While the rally in GLP-1 giants has already been substantial, the latest Medicare coverage expansion has added a new, powerful growth driver.
For those looking to capitalize on this trend without betting on a single company, specialized Exchange-Traded Funds (ETFs) focused on GLP-1 drugs offer a compelling way to gain diversified exposure to the industry-wide rally.
To understand why these ETFs are poised to benefit, one must first grasp the scale of the obesity drug market's expansion and its growth opportunities in the United States, in addition to the specific impact of this new coverage.
The Booming U.S. Obesity Drug Market
The U.S. weight-loss drug market has experienced explosive growth, driven by a combination of medical innovation and soaring patient demand. According to CDC data, every single U.S. state and territory maintains an obesity prevalence of 25% or higher, with the condition affecting 40% of all U.S. adults. This widespread public health crisis results in nearly $173 billion in annual healthcare expenditures, putting weight-loss drugs, commonly known as GLP-1s, at center stage.
This growth is further fueled by aggressive pipeline expansion from the industry's two dominant players. Eli Lilly recently strengthened its position with the launch of its oral GLP-1, Foundayo, in early April 2026, joining its blockbuster injection Zepbound. Novo Nordisk rolled out an oral version of its flagship Wegovy in January 2026, giving patients a convenient, non-injectable alternative.
Medicare Coverage Unlocks New Growth Opportunities
Obesity among older Americans has risen sharply, nearly doubling over the last few decades to affect roughly 40% of seniors aged 65 and older. The Medicare GLP-1 Bridge program addresses this previously untapped pool by making therapeutics affordable for a massive segment of the 69 million Medicare beneficiaries.
The financial implications are staggering. A Kaiser Family Foundation (KFF) analysis estimates that 3.8 million beneficiaries immediately meet the clinical criteria for the program. KFF projects that if even 10% to 25% of these eligible seniors participate, the program will inject between $1.3 billion and $3.3 billion directly into the market. If adoption reaches 50%, that revenue pipeline balloons up to $10 billion.
Novo Nordisk and Eli Lilly estimate that 15 to 20 million older adults in Medicare could ultimately qualify for their weight loss medications (as cited in CNBC). So, the latest Medicare Coverage of GLP-1 drugs should translate into direct revenue growth for these two drug giants.
This highly visible profit margin may also force other pharma giants to accelerate their pipelines. Pfizer (PFE - Free Report) recently finalized a massive $10 billion acquisition of obesity biotech Metsera to secure long-acting GLP-1 assets, while Amgen (AMGN - Free Report) is aggressively advancing its own experimental weight-loss therapy candidate like maridebart cafraglutide.
Weight Loss ETFs to Rally
To seamlessly capture this expanding ecosystem of the weight loss market, the following specialized ETFs featuring the obesity drug giants are poised to rally in the coming days:
Roundhill GLP-1 & Weight Loss ETF (OZEM - Free Report)
This fund, with net assets worth $54 million, offers exposure to 25 companies that are involved in the manufacturing of weight loss drugs, including GLP-1 agonists. Its top three holdings include: NVO (with 12.96% weightage), LLY (12.69%) and PFE (6.38%). AMGN holds the 10th spot in this fund, with 3.85% weightage.
OZEM has surged 27.1% over the past year. The fund charges 59 basis points (bps) as fees.
Amplify Weight Loss Drug & Treatment ETF (THNR - Free Report)
This fund, with net assets worth $4.4 million, offers exposure to 20 companies that are expected to economically benefit from weight loss drug development. Its top three holdings include: NVO (9.76%), LLY (9.26%) and Scholar Rock (5.71%). AMGN holds the seventh spot in this fund, with 4.58% weightage.
THNR has risen 11.8% over the past year. The fund charges 59 bps as fees.
Tema Heart & Health ETF (HRTS - Free Report)
This fund, with net assets worth $54.6 million, offers exposure to 45 companies advancing prevention and treatment across chronic conditions, including heart disease, diabetes, and obesity. Its top three holdings include: LLY (11.86%), UnitedHealth (5.53%) and NVO (5.22%).
HRTS has rallied 26.5% over the past year. The fund charges 75 bps as fees.